Long Ideas - A Bloomberg article today illustrates the Street’s bullish outlook on Achillion Pharmaceuticals (NASDAQ:ACHN) as a takeover candidate. Following the failure of Hep C compounds being developed … Continue Reading
Read NowLong Ideas - Shares of Halozyme Therapeutics (NASDAQ:HALO) have recovered nicely since the stock was cut in half on news related to the company’s partnered products with Baxter … Continue Reading
Read NowLong Ideas - Amarin Pharmaceuticals (NASDAQ:AMRN) could trade higher as investors digest this morning’s news that Roche’s (OTC:RHHBY) former Head of Global Pharmaceuticals has joined AstraZeneca (NYSE:AZN) as … Continue Reading
Read NowLong Ideas - Catalyst Pharmaceutical Partners (NASDAQ:CPRX) announced that in a direct public offering of 4 million shares of common stock and 1.2MM warrants, it will be raising … Continue Reading
Read NowLong Ideas - Eli Lilly & Co. (NYSE:LLY) announced this morning that its potential treatment to slow the onset of Alzheimer’s Disease, solanezumab, showed favorable effects in its … Continue Reading
Read NowLong Ideas - Spectrum Pharmaceuticals (NASDAQ:SPPI) is defending its Fusilev cancer treatment franchise after a recent article suggested that pricing for the drug had been cut. An article … Continue Reading
Read NowLong Ideas - Australian-listed Prana Biotechnology (ASX:PBT)(NASDAQ:PRAN) gave updates today on the company’s ongoing Phase II trials for lead compound PBT2, a potential treatment for neurodegenerative diseases Alzheimer’s … Continue Reading
Read Now